Ancora Advisors’s Aquestive Therapeutics AQST Stock Holding History

Ancora Advisors’s Portfolio AQST Stock Details AQST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-20,000	Closed	-$58K	–	1971
2025 Q1	$58K	Sell	20,000 -8,997	-31%	-$27.2K	﹤0.01%	983
2024 Q4	$103K	Buy	28,997 +7,751	+36%	+$35.7K	﹤0.01%	848
2024 Q3	$106K	Buy	+21,246	New	+$82.7K	﹤0.01%	808

Other funds holding AQST

BCM

Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PFCS

Pale Fire Capital SE Prague, Czech Republic $1.14B AUM 42.87% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Ancora Advisors's AQST Position: Q2 2025 in Review

Ancora Advisors sold out of Aquestive Therapeutics (AQST) in Q2 2025, closing a stake of 20,000 shares — an estimated $58K sold.

Ancora Advisors first reported a position in AQST in Q3 2024 and held it in 3 quarters. The position peaked at $106K in Q3 2024. 116 funds tracked by Wall St. Rank hold AQST as of Q2 2025.

Ancora Advisors reported no remaining Aquestive Therapeutics position as of Q2 2025 after selling out during the quarter.
Ancora Advisors sold 20,000 Aquestive Therapeutics shares in Q2 2025, an estimated $58K.
Ancora Advisors first reported a position in Aquestive Therapeutics in Q3 2024 and held it in 3 quarters.
Ancora Advisors's Aquestive Therapeutics position peaked at $106K in Q3 2024.
116 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2025.

Based on Ancora Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.